Estrella Immunopharma, Inc.

Estrella Immunopharma is a clinical-stage biopharmaceutical company developing T-cell therapies targeting blood cancers and solid tumors. The company's lead product candidate, EB103, is currently in clinical trials for diffuse large B-cell lymphoma treatment. Additional pipeline candidates in preclinical development include EB104 for diffuse large B-cell lymphoma and acute lymphocytic leukemia, and EB201 for systemic lupus erythematosus. The company maintains a collaborative agreement with Eureka Therapeutics and Imugene Limited to evaluate the combination of Imugene's solid tumor candidate CF33-CD19t with EB103.

Founded in 2006 and headquartered in Emeryville, California, Estrella Immunopharma operates as a subsidiary of Eureka Therapeutics. As a clinical-stage company, the organization does not generate meaningful product revenues and remains dependent on funding from its parent company and external sources to support ongoing research and development activities. The company's operations are concentrated in the United States.